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1
ABSTRACT 1 
Background: Several models for predicting the risk of death in people with chronic 2 
obstructive pulmonary disease (COPD) exist but have not undergone large scale validation in 3 
primary care. The objective of this study was to externally validate these models using 4 
statistical and machine learning approaches. 5 
Methods: We used a primary care COPD cohort identified using data from the UK Clinical 6 
Practice Research Datalink. Age-standardised mortality rates were calculated for the 7 
population by gender and discrimination of ADO (age, dyspnoea, airflow obstruction), COTE 8 
(COPD-specific comorbidity test), DOSE (dyspnoea, airflow obstruction, smoking, 9 
exacerbations) and CODEX (comorbidity, dyspnoea, airflow obstruction, exacerbations) at 10 
predicting death over 1-3 years measured using logistic regression and a support vector 11 
machine learning (SVM) method of analysis. 12 
Results: The age-standardised mortality rate was 32.8 (95%CI 32.5-33.1) and 25.2 (95%CI 13 
25.4-25.7) per 1000 person years for men and women respectively. Complete data were 14 
available for 54879 patients to predict 1-year mortality. ADO performed the best (c-statistic 15 
of 0.730) compared with DOSE (c-statistic 0.645), COTE (c-statistic 0.655) and CODEX (c-16 
statistic 0.649) at predicting 1-year mortality. Discrimination of ADO and DOSE improved 17 
discrimination at predicting 1-year mortality when combined with COTE comorbidities (c-18 
statistic 0.780 ADO+COTE; c-statistic 0.727 DOSE+COTE). Discrimination did not change 19 
significantly over 1-3 years. Comparable results were observed using SVM. 20 
Conclusion: In primary care, ADO appears superior at predicting death in COPD. 21 
Performance of ADO and DOSE improved when combined with COTE comorbidities suggesting 22 
better models may be generated with additional data facilitated using novel approaches. 23 
24 
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INTRODUCTION 1 
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality 2 
worldwide.[1,2] Despite the large excess mortality associated with COPD, few interventions 3 
have been shown to reduce overall mortality, which include smoking cessation, long-term 4 
oxygen therapy (LTOT) and lung volume reduction surgery in small subsets of COPD 5 
patients.[3-6] Predicting death in people with COPD could help to inform patients about their 6 
disease course, and help health care professionals decide when to offer or stop therapies 7 
including when to consider palliative care. However, current guidelines on the management 8 
of COPD provide limited guidance on the prognostic assessment related to these factors, 9 
despite increasing attention to the development of risk scores for predicting future health 10 
outcomes in people with COPD.[7,8]  11 
 12 
Risk scores are used to guide decision-making and often use a very small number of variables 13 
to predict the outcome of interest, with a trade-off between predictive performance and being 14 
user-friendly. Variables are often identified through a selection process involving modelling 15 
large amounts of data to find combinations of predictive factors with high sensitivity and 16 
specificity. Novel machine learning approaches offer several potential advantages over 17 
standard regression for risk prediction but still require validation in several applications before 18 
being accepted in mainstream clinical research.[9,10] 19 
 20 
Several risk scores have been developed attempting to predict death in people with COPD, 21 
including ADO (age, dyspnoea and airflow obstruction), BODE (body mass index, airflow 22 
obstruction, dyspnoea and exercise capacity), COTE (COPD specific comorbidity test) and 23 
DOSE (dyspnoea, obstruction, smoking and exacerbations).[11-14] These risk scores have 24 
predominantly been developed in selected populations, often from secondary care, who may 25 
differ in terms of prognosis to those in primary care. Such characteristics include the 26 
prevalence and severity of comorbidities, which may differ between primary and secondary 27 
3
  
care COPD populations. It is therefore uncertain how generalizable the predictive performance 1 
of these risk scores are to people in primary care. The performance of ADO at predicting two 2 
year mortality has been evaluated in small population samples from primary care and have 3 
reported promising results.[15] However, larger cohorts are required to properly evaluate the 4 
predictive performance of these risk scores in primary care patients.[16]  5 
 6 
The aim of this study was to evaluate several existing risk scores for mortality in COPD over 7 
multiple time periods with a large representative COPD population from primary care, using 8 
both traditional and a machine learning approach. 9 
 10 
MATERIAL AND METHODS 11 
Data source 12 
Data from the UK Clinical Practice Research Datalink (CPRD) were used to validate several 13 
clinical prediction rules assessing mortality in people with COPD. CPRD is a large source of 14 
longitudinal UK electronic primary care medical records that has been widely used for 15 
research. It contains anonymised information on symptoms, diagnoses, tests, referrals to 16 
secondary care and death for over 13 million people, of whom 4.4 million are currently 17 
registered with a practice that is contributing data to CPRD, representing about 9% of the UK 18 
population. Data within CPRD are predominantly recorded using Read Codes, a hierarchical 19 
thesaurus of coded clinical terms used in UK primary care. General practices and patients 20 
within CPRD are required to meet defined quality standards in order to contribute data. Around 21 
60% of the patients included in the CPRD have been linked to ONS, an administrative 22 
database containing information on all death registrations in England. Diagnoses in ONS are 23 
recorded using International Classification of Disease version 10 (ICD-10) codes. 24 
 25 
Study approval 26 
4
  
The study was approved by the Independent Scientific Advisory Committee for Medicines and 1 
Healthcare products Regulatory Agency database research (protocol number 15_112R). 2 
 3 
Population 4 
A cohort of 204473 patients with actively treated COPD present within CPRD between 5 
01.01.2000 to 01.04.2014 was identified using a validated Read code algorithm.[17] All 6 
patients were required to have spirometry confirmed COPD with a forced expiratory volume 7 
in 1 second (FEV1)/forced vital capacity (FVC) ratio of <0.7 and be acceptable for use in 8 
research (a marker of internal quality control by CPRD). Cohort entry was defined as the latest 9 
date of the following: having been registered with a general practice providing up-to-standard 10 
data for at least 1 year prior to cohort entry; issued ≥1 COPD-related medication (defined by 11 
short or long-acting beta2-agonists, short or long-acting muscarinic antagonist, inhaled 12 
steroids, methylxanthines); and date of incident COPD Read code diagnosis. Cohort exit was 13 
defined by the earliest of: death, transfer out from the general practice, date of last data 14 
collection, or end of the study period. 15 
 16 
Clinical prediction rules 17 
A cross-section of the cohort was taken at 01/04/2011 for validating the clinical prediction 18 
rules. This date was selected based upon optimally recorded data in primary care whilst 19 
allowing sufficient time for follow-up. Three clinical prediction rules for predicting mortality in 20 
people with COPD were chosen for validation in primary care, namely the ADO (including the 21 
updated ADO index score which differs by allocating scores at different cutpoints of the three 22 
variables)[18], COTE and DOSE index scores. A fourth, CODEX (consisting of comorbidity, 23 
dyspnoea, airflow obstruction and the number of severe exacerbations in the previous year, 24 
which was derived to assess short- and medium-term prognosis in hospitalized COPD 25 
patients) was additionally evaluated as a post-hoc analysis.[19] BODE was not chosen 26 
because it requires data on a 6-minute walk test not routinely measured in primary care. 27 
5
  
Percentage predicted FEV1 was either identified from the medical record or calculated based 1 
upon lung function data contained within electronic medical records.[20] COTE is a 2 
comorbidity index consisting of 13 comorbidities that potentially improve the ability to predict 3 
death in people with COPD.[13] The DOSE index score requires data on the number of acute 4 
exacerbations in the previous 12 months. Acute exacerbations were defined by 1) Read codes 5 
for acute exacerbations, and 2) Read codes for respiratory tract infections or respiratory 6 
symptoms combined with same-day oral corticosteroid prescriptions.[20] For each of these 7 
models, risk scores have been created attempting to stratify people at increased risk of 8 
mortality (supplementary table S1 and S2). For CODEX, the Charlson comorbidity score was 9 
calculated consisting of 15 comorbidities.[19] 10 
 11 
Statistical analysis  12 
The incidence of death in people COPD was calculated over the study period directly age-13 
standardised to the 2013 European Standard Population. The numerator consisted of the 14 
number of deaths and the denominator the number of person years. The performance of the 15 
ADO, DOSE and COTE was validated using multivariable logistic regression, generating odds 16 
ratios and assessing each models discrimination by producing area under the receiver 17 
operator characteristic (AUC) curves and reporting the c-statistic. This was done first for each 18 
corresponding risk score and second with each of the individual variables within each clinical 19 
prediction rule. Predictive performance was assessed over a one, two and three year follow-20 
up period, which builds on the scope of existing studies.  21 
 22 
Sensitivity analysis 23 
Logistic regression analysis was repeated for each of the risk scores using only percentage 24 
predicted FEV1 and MRC dyspnoea score recorded in the previous year vs. ever recorded to 25 
ensure that the timing of recording had no impact on the results of risk prediction models. 26 
 27 
6
  
Machine learning analysis 1 
For each risk score, results from logistic regression modelling were compared with those from 2 
a support vector machine (SVM) algorithm that provided a binary output as used in logistic 3 
regression. The LibSVM implementation of support vector machines was used.[22]  All 4 
patients were grouped by their GP practice resulting in a total of 618 practices in the cohort. 5 
The data was then randomly split into two sets; a training/testing data set consisting of 80% 6 
(494) of practices, and a validation data set consisting of the remaining 20% (124) of 7 
practices.  The training/testing data set was used to train the models and optimal parameter 8 
estimation.  The optimal values for parameters Cost and Gamma were found by a grid search, 9 
evaluated as the optimal reported AUC curves and c-statistic, using a 10-fold cross-validation 10 
approach.  The optimal kernel type was also evaluated by comparing results from Linear, 11 
Polynomial, and Radial Basis Function (RBF) kernels, with the RBF kernel performing the best.  12 
Class weighting was used to improve prediction accuracy and 95% confidence intervals were 13 
generated through bootstrapping.  14 
 15 
RESULTS 16 
A total of 204473 patients with COPD were identified in CPRD. The cohort contained 1.5 million 17 
person-years follow-up (mean 7.1 years per patient) during which 65878 patients died during 18 
follow-up (32.3%). The age-standardised mortality rate in people aged 40 and over was 32.8 19 
(95%CI 32.5-33.1) per 1000 person-years for men and 25.2 (95%CI 25.4-25.7) per 1000 20 
person years for women for the cohort. The trend in age-standardised mortality is shown in 21 
figure 1. Mortality rates in women appeared fairly level throughout the study period whilst 22 
mortality rates for older men showed a downward trend from 2006.  23 
 24 
Validation of ADO, DOSE, COTE and CODEX in people with COPD in primary care 25 
At 01/04/2011, 70312 eligible patients alive and registered with a GP practice were identified, 26 
of which 54879 patients (78.0%), 53707 patients (76.2%), and 52684 (75.0%) patients had 27 
7
  
complete data for analysis over a 1, 2 and 3-year period respectively. Characteristics of 1 
patients present in the cohort for the one year period as of 01/04/2011 are shown in table 1. 2 
A total of 2811 (5.1%) patients had died at 1 year, 5652 (10.5%) had died at 2 years and 3 
8083 (15.3%) had died at 3 years. Odds ratios for each clinical prediction rule over a 1, 2 and 4 
3-year period are shown in table 2 and supplementary tables S3 and S4 respectively. An 5 
incremental increase in the size of the odds ratio per unit increase in score was observed for 6 
ADO, DOSE and CODEX index scores but not for the COTE index score. 7 
 8 
The discriminative performance of ADO, DOSE, CODEX and COTE for predicting the risk of 9 
death in people with COPD over a 1, 2 and 3-year period in primary care using a statistical 10 
approach are presented in table 3. The ADO index score had the best discrimination with a 1 11 
year c-statistic of 0.730 compared with the DOSE index score (c-statistic 0.645). The updated 12 
ADO index score did not perform better than the original ADO index score. Discrimination 13 
improved slightly when actual clinical variables were modelled instead of the respective index 14 
scores (supplementary table S5). In general, discrimination did not change significantly over 15 
1, 2 or 3-years. Discrimination of COTE modelled using only comorbidities was similar to DOSE 16 
(c-statistic 0.655 for 1 year, 0.657 for 2 year and 0.674 for 3-year models) and to CODEX (c-17 
statistic 0.649). Discrimination of both ADO and DOSE significantly improved when modelled 18 
in combination with comorbidities used to calculate the COTE index score (c-statistic 0.730 19 
for 1 year ADO index without COTE vs. 0.780 for 1 year ADO index with COTE, c-statistic 20 
0.645 for 1 year DOSE index without COTE vs. 0.727 for 1 year DOSE index with COTE).   21 
 22 
Comparative performance of support vector machine learning methodology 23 
The discriminative performance of ADO, DOSE, CODEX and COTE for predicting the risk of 24 
death in people with COPD over a 1, 2 and 3-year period in primary care, using a SVM method 25 
of analysis is presented in table 3. Similar to the statistical approach, the ADO index score 26 
performed the best with a 1 year c-statistic of 0.723 compared with 1 year DOSE index score 27 
8
  
c-statistic of 0.654, COTE index score of 0.650 and CODEX index score of 0.651. 1 
Discrimination again improved slightly when actual features were modelled instead of index 2 
scores (supplementary table S5). Similarly, discriminative performance did not change 3 
significantly when modelled over 1, 2 or 3-year period. Predictive performance of the ADO 4 
and DOSE index scores again improved with the addition of COTE comorbidities. Overall 5 
discrimination of SVM using the limited feature set contained within ADO, DOSE, CODEX and 6 
COTE was comparable to results obtained from logistic regression. 7 
 8 
DISCUSSION 9 
Using electronic medical record data from primary care we were able to perform the largest 10 
external validation to date for several well-recognised clinical prediction rules derived to 11 
predict the risk of death in people with COPD. This study demonstrated that the ADO index 12 
score performed the best compared to the DOSE, COTE and CODEX index scores, and that 13 
the performance of ADO and DOSE significantly improved when COTE comorbidities were 14 
incorporated within each model. In this regard, a model with a c-statistic above 0.70 is 15 
generally considered as good and 0.80 and above is considered excellent. Although the 16 
addition of the 12 COTE comorbidities significantly improved the performance of both the ADO 17 
and DOSE index scores, model performance of COTE comorbidities alone was relatively poor 18 
and similar to that of CODEX. For all clinical prediction rules, model performance were similar 19 
whether predicting death over a 1, 2 or 3-year time period although the number of patients 20 
who died in absolute terms differed. 21 
 22 
In a small primary care population consisting of 646 selected patients from primary care, the 23 
ADO index was shown to predict 2-year mortality with a c-statistic of 0.78 (95% CI 0.71–24 
0.84), whilst in a larger multicentre study with many secondary care patients discrimination 25 
of ADO was substantially lower when externally validated with a c-statistic 0.70 (95%CI 0.67-26 
0.73).[15, 18] However, ADO could be useful at discriminating survival in patients receiving 27 
9
  
LTOT as an ADO score greater than 5 has been shown to have a 20% chance of survival at 4 1 
years compared to 65% of people with an ADO score of 2 or 3.[23] 2 
 3 
Although a higher DOSE index score is associated with greater risk of mortality, our study 4 
found that it consistently performed less well than ADO at predicting 1, 2 and 3-year mortality 5 
in primary care COPD patients.[24] Whilst ADO seems a better predictor of mortality than 6 
DOSE, DOSE may be a better predictor of exacerbations and hospitalisation, probably because 7 
the number of exacerbations in the previous 12 months is a component of DOSE and in many 8 
cases past events are usually highly correlated with future events.[13]  9 
 10 
Comorbidities in the COTE index score were derived from 1664 COPD secondary care patients 11 
and had relatively poor discrimination at predicting mortality when derived with an c-statistic 12 
of only 0.66, similar to our findings.[14] Although the discriminative performance of COTE 13 
appears limited when used alone, discrimination significantly improved when combined with 14 
variables from ADO and DOSE. A similar  observation occurred with CODEX which had better 15 
discrimination than the ADO and DOSE index scores for predicting 1-year mortality in COPD 16 
patients following hospital discharge, although its performance was poorer than the 17 
combination of ADO or DOSE with COTE comorbidities n our primary care population and 18 
similar to the predictive performance of 1 year mortality in the original secondary care 19 
derivation cohort (c-statistic 0.67).[19] However, the problem with many of these studies is 20 
that they contain heterogeneous, partially selected populations recruited at different stages 21 
of disease, with some cohorts at risk of bias from loss to follow-up. Heterogeneity is also seen 22 
in the time frame chosen to predict mortality, all of which make it difficult to compare models, 23 
which our study partly attempts to overcome by using a large representative real world 24 
population.  25 
 26 
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We used only patients with complete data for analysis which is a potential limitation of our 1 
study. Although methods such as multiple imputation are available they were not used 2 
because it was uncertain whether data were missing at random and the applicability of 3 
prediction models in routine care rely on such data actually being recorded. We also have no 4 
objective measure for the quality of pulmonary function testing which may vary in primary 5 
care, although evidence suggests that quality of spirometry is high with a previous validation 6 
study showing that 98.6% of spirometry traces in primary care were of adequate quality.[20] 7 
Although we use a validated approach to identifying exacerbations it is uncertain whether all 8 
were captured which could influence the performance of the DOSE index score. The accuracy 9 
of models incorporating multiple comorbidities will be influenced by the quality of diagnostic 10 
recording which may vary between data sources. However, the validity of many diagnoses 11 
within CPRD is considered high.[25-27] 12 
 13 
The potential utility of using prediction models to drive clinical care is appealing. Prediction 14 
models such as ADO (e.g. score of 5 or more) may be useful in targeting high risk individual 15 
for interventions and trials of treatment. In the era of ‘big data’, machine learning approaches 16 
offer potential advantages in being able to process large amounts of clinical data such as 17 
those contained with electronic medical records. However, machine learning approaches have 18 
infrequently been applied to such data and therefore require to be validated before widespread 19 
adoption. This seems to be particularly important as our study has shown that predictive 20 
performance can be improved by incorporating more clinical information, in this example 21 
using COTE comorbidities. However, incorporating larger amounts of data may be infeasible 22 
to interpret through human factors alone. Using a limited feature set, SVM performs as well 23 
as standard logistic regression helping to validate this approach which could now be applied 24 
to a large data set that includes far more clinical data (such as blood results, prescriptions, 25 
pattern of health care access and social care data). These results suggest that other machine 26 
learning approaches such as large-scale deep learning models could also be evaluated to 27 
11
  
harness the full potential of very large data repositories. The challenge now is to create better 1 
clinical prediction models to stratify patients at greatest risk and identify ways of integrating 2 
them into routine clinical practice. One such way would be to integrate such models at annual 3 
COPD reviews that are frequently part of routine care to help target interventions and provide 4 
prognostic information to clinicians and patients including planning of palliative care services 5 
by identifying people at high risk of dying within the next year. It would also be important for 6 
helping to stratify or withdraw certain treatments helping to rationalise resources or identify 7 
vulnerable groups that should receive better access to care.  8 
 9 
CONCLUSIONS 10 
The ADO clinical prediction rule combined with COTE comorbidities performs relatively well at 11 
predicting the risk of death in people with COPD in primary care using data from electronic 12 
medical records. A SVM method of analysis seems a valid alternative to risk prediction 13 
modelling using such data and has potential to be used more widely with larger more 14 
complicated data sets. 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
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TABLES 1 
Table 1. Characteristics of eligible COPD patients alive and registered with a general 2 
practice during a cross-section of the cohort on 01/04/2011 for predicting 1-year 3 
mortality. 4 
Variable 1 year COPD  
cross-section 
Number of patients 54879 
Age, ± SD 74.1 ± 10.3 
Female, % 46.2 
FEV1 % predicted, ± SD 59.5 ± 20.4 
MRC dyspnoea score, %  
 0 16.0 
 1 38.2 
 2 26.7 
 3 16.0 
 4 3.1 
Exacerbation in the last year, %  
 0-1 84.0 
 2 7.5 
 3 3.7 
 >3 4.8 
Smoking status, %  
 Non-smoker 68.0 
 Smoker 32.0 
COTE comorbidities, %   
 lung cancer 2.8 
 oesophageal cancer 0.3 
 pancreatic cancer 0.2 
 breast cancer 1.0 
 other cancers  
 anxiety 12.9 
 liver cirrhosis 0.4 
 atrial fibrillation/flutter 9.3 
 diabetes with neuropathy 0.7 
 pulmonary fibrosis 0.4 
 congestive heart failure 5.7 
 gastric/duodenal ulcers 1.4 
 coronary artery disease 7.6 
 5 
 6 
 7 
 8 
 9 
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Table 2. Performance of ADO, DOSE, COTE and CODEX at predicting risk of death in 1 
people with COPD from primary care over a 1-year period using logistic regression. 2 
 
CPR index score 
Percent dead at 
1 year (%) 
 
Odds ratio 
 
95% confidence interval 
ADO   
 
0-1 0.5 Reference - 
2 1.0 1.97 1.00-3.89 
3 1.7 3.37 1.78-6.38 
4 3.1 6.23 3.32-11.69 
5 5.7 11.61 6.20-21.72 
6 7.7 16.12 8.61-30.19 
7 12.6 27.93 14.91-52.34 
8 18.8 44.72 23.74-84.24 
9 28.0 75.13 38.85-145.3 
10 39.1 124.07 52.59-292.7 
DOSE    
0 2.8 Reference - 
1 3.6 1.32 1.16-1.51 
2 5.4 2.00 1.76-2.28 
3 6.8 2.57 2.23-2.95 
4 10.8 4.26 3.69-4.93 
5 12.4 4.97 4.17-5.92 
6 17.3 7.36 5.83-9.30 
7 20.7 9.22 6.24-13.63 
8 21.7 9.80 3.62-26.52 
COTE    
0 3.5 Reference - 
1 7.7 2.24 1.93-2.60 
2 5.6 1.65 1.48-1.85 
3 8.9 2.73 2.29-3.25 
4 7.7 2.31 1.88-2.85 
5 11.6 3.66 2.68-5.01 
6 5.9 1.74 1.53-1.97 
7 10.6 3.30 2.54-4.29 
8 10.7 3.35 2.84-3.95 
9 10.1 3.14 2.21-4.48 
≥10 14.6 4.76 3.86-5.88 
CODEX    
0 1.8 Reference - 
19
  
1 2.4 1.36 1.04-1.79 
2 3.5 2.02 1.57-2.62 
3 5.1 3.02 2.34-3.89 
4 6.5 3.87 3.00-4.98 
5 7.5 4.56 3.52-5.90 
6 9.5 5.84 4.49-7.60 
7 11.7 7.42 5.60-9.82 
8 13.8 8.97 6.43-12.51 
9 34.3 29.16 13.95-60.95 
10 50.0 55.88 7.76-402.5 
      Index score modelled as categorical variable. 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
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Table 3. Discriminative performance for ADO, DOSE, COTE and CODEX in people with 1 
COPD in primary care with logistic regression and support vector machine learning 2 
analysis. 3 
 
Clinical Prediction Rule 
1 year c-statistic 
(95%CI) 
2 year c-statistic 
(95%CI) 
3 year c-statistic 
(95%CI) 
Logistic regression    
ADO Index score 
0.730 (0.721-0.739) 0.734 (0.728-0.741) 0.732 (0.727-0.738) 
Updated ADO Index score 
0.720 (0.710-0.729) 0.725 (0.718-0.731) 0.724 (0.719-0.730) 
DOSE Index score 
0.645 (0.634-0.656) 0.649 (0.642-0.657) 0.645 (0.638-0.651) 
COTE Index score only 0.655 (0.644-0.666) 0.657 (0.650-0.665) 0.674 (0.667-0.680) 
COTE + ADO index score 0.780 (0.771-0.788) 0.789 (0.783-0.795) 0.799 (0.794-0.804) 
COTE + DOSE index score 
0.727 (0.717-0.737) 0.739 (0.732-0.746) 0.748 (0.742-0.754) 
CODEX Index score* 
0.649 (0.639-0.659) 0.656 (0.649-0.663) 0.652 (0.646-0.648) 
Support Vector Machine    
ADO Index score  0.723 (0.700-0.741)  0.729 (0.714-0.743)  0.732 (0.721-0.745) 
Updated ADO Index score 0.716 (0.696-0.736) 0.722 (0.706-0.736) 0.723 (0.714-0.739) 
DOSE Index score  0.654 (0.630-0.678)  0.650 (0.632-0.668)  0.647 (0.631-0.660) 
COTE Index score  0.650 (0.627-0.673)  0.651 (0.633-0.668)  0.670 (0.655-0.685) 
COTE + ADO index scores  0.778 (0.758-0.794)  0.781 (0.768-0.795)  0.796 (0.785-0.807) 
COTE + DOSE index scores  0.736 (0.711-0.757)  0.736 (0.720-0.751)  0.740 (0.726-0.754) 
CODEX Index score* 
0.651 (0.627-0.671) 0.657 (0.639-0.673) 0.649 (0.635-0.663) 
 4 
Models with a C-statistic ≥0.7 are generally considered good and those ≥0.8 as excellent.  5 
*Post-hoc analysis. 6 
 7 
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 1 
FIGURE LEGENDS 2 
 3 
Figure 1. Trends in all-cause mortality in people with COPD in UK primary care by 4 
age category, A) women, B) men.  5 
 6 
 7 
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